Filing Details

Accession Number:
0001562180-20-005100
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-10 21:15:52
Reporting Period:
2020-07-08
Accepted Time:
2020-07-10 21:15:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1704483 Robert Berman C/O Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven CT 06510
Special Projects & Med Ovrsght No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2020-07-08 58,404 $0.61 58,745 No 4 M Direct
Common Shares Disposition 2020-07-08 55,626 $75.25 3,119 No 4 S Direct
Common Shares Disposition 2020-07-08 2,778 $75.29 341 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Employee Stock Option (right to buy) Disposition 2020-07-08 58,404 $0.00 58,404 $0.61
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-11-25 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Shares 550,000 Indirect By Berman Family Trust 2013
Common Shares 240,500 Indirect By Berman Marital Trust 2013
Common Shares 50 Indirect Owned by Spouse
Footnotes
  1. These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 - $75.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.00 - $76.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  4. The option, representing a right to purchase a total of 225,000 shares, was granted on November 26, 2014, and vested in four equal installments on November 26, 2014, 2015, 2016 and 2017